Table 2.
EV isolation and characterization methods of current EV-based preclinical studies in models of bronchopulmonary dysplasia.
| REQ1: EV Quantification | REQ2: Protein Characterization | REQ3: Single EVs | ||||||
|---|---|---|---|---|---|---|---|---|
| Publication | Isolation Method | BCA | NTA | Presence of Trans-Membrane Proteins | Presence of Cytosolic Proteins | Absence of non-EV Proteins | TEM | NTA |
| Willis 2018 [32] | TFF + UC | ✓ | CD63, CD9, CD81 | HSP70 | ✓ | ✓ | ||
| Porzionato 2019 [36] | TFF | ✓ | CD63, CD9, CD81 | ANNEXIN V | ALBUMIN | ✓ | ||
| Braun 2018 [37] | UC | ✓ | ✓ | CD63, CD9, CD81 | ✓ | ✓ | ||
| Ahn 2018 [38] | UC | ✓ | ✓ | CD63, CD9 | GM130, FIBRILLARIN | ✓ | ✓ | |
| Chaubey 2018 [39] | UC | ✓ | ✓ | CD63, CD81 | ALIX1 | TGN48 | ✓ | ✓ |
| Li 2020 [40] | UC | ✓ | CD63, CD9, CD81 | HSP70 | ✓ | |||
| Willis 2020 [33] | TFF + UC | ✓ | CD63, CD9, CD81 | FLOT1, ALIX, TSG101 | GM130 | ✓ | ✓ | |
| Abele 2021 [41] | TFF + UC | ✓ | ✓ | ✓ | ||||
| Porzionato 2021 [42] | TFF | ✓ | CD63, CD9, CD81 | ANNEXIN V | ALBUMIN | ✓ | ||
| Reis 2021 [34] | TFF + UC | ✓ | CD63, CD81 | TSG101, SDCBP | CALNEXIN | ✓ | ✓ | |
| Willis 2021 [35] | TFF + UC | ✓ | CD63, CD9 | FLOT1, ALIX, TSG101 | GM130, CALNEXIN | ✓ | ✓ | |
| You 2020 [43] | UC | ✓ | ✓ | CD63 | ALIX | ✓ | ✓ | |
| Wu 2021 [44] | UC | ✓ | ✓ | CD63, CD9 | CALNEXIN | ✓ | ✓ | |
| Lithopoulos 2022 [45] | UC | ✓ | ✓ | CD63 | FLOT1 | CALNEXIN | ✓ | ✓ |
| Ai 2021 [46] | UC | ✓ | ✓ | CD63, CD9 | FLOT1 | ✓ | ✓ | |
Studies highlighted in light green partially fulfilled the MISEV2018 criteria for EV characterization, whereas studies highlighted in dark green fulfilled all MISEV2018 criteria. Abbreviations: BCA: bicinchoninic acid protein assay; NTA: nanoparticle tracking analysis; TEM: transmission electron microscopy; TFF: tangential flow filtration; UC: ultracentrifugation.